Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis-Reference-Cited by-同舟云学术

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Published:2023-09 Issue:10 Volume:21 Page:2597-2605.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Siddiqui Mohammad Shadab^ORCID,Parmar Deven,Sheikh Farheen,Sarin Shiv Kumar,Cisneros Laura,Gawrieh Samer,Momin Taufik^ORCID,Duseja Ajay,Sanyal Arun J.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference31 articles.

1. Long-term follow-up of patients with NAFLD and elevated liver enzymes;Ekstedt;Hepatology,2006

2. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up;Söderberg;Hepatology,2010

3. Prospective study of outcomes in adults with nonalcoholic fatty liver disease;Sanyal;N Engl J Med,2021

4. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease;Targher;N Engl J Med,2010

5. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes;Mantovani;PLoS One,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Sesquiterpenoids from the Mangrove-Derived Fungus Talaromyces sp. as Modulators of Nuclear Receptors;Marine Drugs;2024-09-03

2. Sesaminol alters phospholipid metabolism and alleviates obesity‐induced NAFLD;The FASEB Journal;2024-07-22

3. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes;Atherosclerosis;2024-07

4. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future;Biomedicines;2024-06-21

5. Raloxifene-driven benzothiophene derivatives: Discovery, structural refinement, and biological evaluation as potent PPARγ modulators based on drug repurposing;European Journal of Medicinal Chemistry;2024-04